These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38599550)

  • 1. Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.
    Tolksdorf B; Heinze J; Niemeyer D; Röhrs V; Berg J; Drosten C; Kurreck J
    Antiviral Res; 2024 Jun; 226():105879. PubMed ID: 38599550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SARS-CoV-2 Replication by a Small Interfering RNA Targeting the Leader Sequence.
    Tolksdorf B; Nie C; Niemeyer D; Röhrs V; Berg J; Lauster D; Adler JM; Haag R; Trimpert J; Kaufer B; Drosten C; Kurreck J
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of SARS-CoV-2 Replication by Self-Assembled siRNA Nanoparticles Targeting Multiple Highly Conserved Viral Sequences.
    Sun J; Lu S; Xiao J; Xu N; Li Y; Xu J; Deng M; Xuanyuan H; Zhang Y; Wu F; Jin W; Liu K
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNA targeting the leader sequence of SARS-CoV inhibits virus replication.
    Li T; Zhang Y; Fu L; Yu C; Li X; Li Y; Zhang X; Rong Z; Wang Y; Ning H; Liang R; Chen W; Babiuk LA; Chang Z
    Gene Ther; 2005 May; 12(9):751-61. PubMed ID: 15772689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirement of the N-terminal region of nonstructural protein 1 in cis for SARS-CoV-2 defective RNA replication.
    Terasaki K; Makino S
    J Virol; 2024 Sep; 98(9):e0090024. PubMed ID: 39194239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
    Bowden-Reid E; Ledger S; Zhang Y; Di Giallonardo F; Aggarwal A; Stella AO; Akerman A; Milogiannakis V; Walker G; Rawlinson W; Turville S; Kelleher AD; Ahlenstiel C
    Antiviral Res; 2023 Sep; 217():105677. PubMed ID: 37478918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA.
    Yamasaki M; Saso W; Yamamoto T; Sato M; Takagi H; Hasegawa T; Kozakura Y; Yokoi H; Ohashi H; Tsuchimoto K; Hashimoto R; Fukushi S; Uda A; Muramatsu M; Takayama K; Maeda K; Takahashi Y; Nagase T; Watashi K
    Antiviral Res; 2024 Oct; 230():105992. PubMed ID: 39181215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion.
    Vora SM; Fontana P; Mao T; Leger V; Zhang Y; Fu TM; Lieberman J; Gehrke L; Shi M; Wang L; Iwasaki A; Wu H
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35149555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of SARS-CoV-2 coronavirus proliferation by designer antisense-circRNAs.
    Pfafenrot C; Schneider T; Müller C; Hung LH; Schreiner S; Ziebuhr J; Bindereif A
    Nucleic Acids Res; 2021 Dec; 49(21):12502-12516. PubMed ID: 34850109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers.
    Rosenke K; Leventhal S; Moulton HM; Hatlevig S; Hawman D; Feldmann H; Stein DA
    J Antimicrob Chemother; 2021 Jan; 76(2):413-417. PubMed ID: 33164048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread.
    Ambike S; Cheng CC; Feuerherd M; Velkov S; Baldassi D; Afridi SQ; Porras-Gonzalez D; Wei X; Hagen P; Kneidinger N; Stoleriu MG; Grass V; Burgstaller G; Pichlmair A; Merkel OM; Ko C; Michler T
    Nucleic Acids Res; 2022 Jan; 50(1):333-349. PubMed ID: 34928377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eight-amino-acid sequence at the N-terminus of SARS-CoV-2 nsp1 is involved in stabilizing viral genome replication.
    Ueno S; Amarbayasgalan S; Sugiura Y; Takahashi T; Shimizu K; Nakagawa K; Kawabata-Iwakawa R; Kamitani W
    Virology; 2024 Jul; 595():110068. PubMed ID: 38593595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses.
    Martinez DR; Moreira FR; Catanzaro NJ; Diefenbacher MV; Zweigart MR; Gully KL; De la Cruz G; Brown AJ; Adams LE; Yount B; Baric TJ; Mallory ML; Conrad H; May SR; Dong S; Scobey DT; Nguyen C; Montgomery SA; Perry JK; Babusis D; Barrett KT; Nguyen AH; Nguyen AQ; Kalla R; Bannister R; Feng JY; Cihlar T; Baric RS; Mackman RL; Bilello JP; Schäfer A; Sheahan TP
    Sci Transl Med; 2024 May; 16(748):eadj4504. PubMed ID: 38776389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity.
    Rand U; Kupke SY; Shkarlet H; Hein MD; Hirsch T; Marichal-Gallardo P; Cicin-Sain L; Reichl U; Bruder D
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of SARS-CoV replication by siRNA.
    Wu CJ; Huang HW; Liu CY; Hong CF; Chan YL
    Antiviral Res; 2005 Jan; 65(1):45-8. PubMed ID: 15652970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2.
    Chowdhury UF; Sharif Shohan MU; Hoque KI; Beg MA; Sharif Siam MK; Moni MA
    Genomics; 2021 Jan; 113(1 Pt 1):331-343. PubMed ID: 33321203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad-Spectrum Antiviral Activity of 3D8, a Nucleic Acid-Hydrolyzing Single-Chain Variable Fragment (scFv), Targeting SARS-CoV-2 and Multiple Coronaviruses In Vitro.
    Lee G; Budhathoki S; Lee GY; Oh KJ; Ham YK; Kim YJ; Lim YR; Hoang PT; Lee Y; Lim SW; Kim JM; Cho S; Kim TH; Song JW; Lee S; Kim WK
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33918914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.
    Cheng K; Martin-Sancho L; Pal LR; Pu Y; Riva L; Yin X; Sinha S; Nair NU; Chanda SK; Ruppin E
    Mol Syst Biol; 2021 Nov; 17(11):e10260. PubMed ID: 34709707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.